MedTrace Logo

Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

NCT00600093 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Conditions

  • Parkinson Disease
  • Perioperative Care

Interventions

DRUG

Amantadine

IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Aeyal Raz, MD,PhD · Rabin Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600093 on ClinicalTrials.gov